VeryTop.ORG

Så meget er 80 gram oksekød. Det er den mængde oksekød plejehjemsbeboere i København må få. Ikke om dagen, men om ugen. For klimaets skyld. Det har Københavns Kommune bestemt. Når man kommer på plejehjem, har man typisk et år tilbage at leve i. Men Københavns Kommune mener, at dette er det helt rigtige tidspunkt at påtvinge borgerne nye spisevaner. Danskerne spiser typisk 300 gram oksekød om ugen – altså næsten 4 gange mere end den ration, plejehjemsbeboerne bliver tilkendt. Dette formynderi bør stoppe. Plejehjemsbeboere har typisk betalt skat hele deres liv ud fra den forventning, at velfærdsstaten tager sig dem, når de får brug for de. De fortjener pleje og omsorg, ikke formynderi.

Scatman John, the man who transformed his stuttering into a unique art

Ever lost an argument and only thought of the perfect comeback three hours later? This book is for future you. Available on Amazon amazon.co.uk/dp/B0FQWS714M/ amazon.com.au/dp/B0FQWS714M/

@Inc Interesting, but still very early. Preclinical findings around GLP-1s and Alzheimer’s-related proteins are another sign that these drugs may have effects far beyond weight loss. The key is separating promise from proof. More context here: amazon.com/dp/B0GFDG6B2X

A new review of preclinical studies suggests GLP-1 drugs like Ozempic may reduce key proteins linked to Alzheimer’s disease. trib.al/5nkq84g

@FirstSquawk Ozempic tablets could make the GLP-1 market even more mainstream. An oral version changes convenience, adoption, and patient expectations—but it also makes it more important to understand doses, absorption, risks, and how pills differ from injections. amazon.com/dp/B0GFDG6B2X

NOVO NORDISK WILL LAUNCH OZEMPIC® TABLETS IN THE US ON MAY 4, THE FIRST ORAL PEPTIDE GLP-1 DRUG APPROVED BY THE FDA FOR ADULTS WITH TYPE 2 DIABETES.

@eduardomenoni Si más pacientes van a tener acceso a los GLP-1, más importante será que estén bien informados. No basta con saber cuánto cuestan: hay que entender beneficios, riesgos, efectos secundarios, pérdida muscular, uso a largo plazo y qué pasa al dejarlos. amazon.es/dp/B0FSYRZ284/

🇺🇸 | El presidente Donald Trump anuncia que los pacientes de Medicare comenzarán a recibir medicamentos para la pérdida de peso como Ozempic por $50 AL MES a partir del 1 de julio. ¡Actualmente cuesta 1.300 USD ! Eso es una REDUCCIÓN ENORME para favorecer a la gente 🔥.

@VladTheInflator Good framing. The issue isn’t “GLP-1s destroy bones” in a simple way—it’s rapid weight loss, lower intake, muscle loss, and reduced loading all interacting. That’s why nutrition, resistance training, and monitoring matter during treatment. More context 👇 amazon.com/dp/B0GFDG6B2X

This disinformation is floating around about Glp-1s I'm not a doctor, I just talk shit online, but here's what AI says: Basically since you're not fat, your bones don't need to be as dense plus nutrient intake. Fix it with calcium and weights. "Primarily linked to rapid weight loss itself rather than a unique "bone-shredding" effect of the drug:Rapid weight loss reduces mechanical loading on bones (less body weight = less stress that signals bones to stay strong). It can also lead to reduced nutrient intake and muscle loss, which compounds the issue. Studies show modest bone mineral density (BMD) reductions: e.g., one 2024 RCT found ~2.6% loss at the hip and ~2.1% at the spine after 52 weeks of semaglutide (comparable to or somewhat more than typical postmenopausal bone loss). Bone resorption increased without full compensation in bone formation. Larger observational data (e.g., 150,000 people) found a modest increase in osteoporosis diagnosis (4% in GLP-1 users vs. ~3% in non-users, or ~30% relative increase). There are also slight rises in fracture risk or related issues like gout in some studies. How to protect your bones if using Ozempic/GLP-1sResistance training and weight-bearing exercise (key to maintaining bone and muscle). Adequate protein, calcium, and vitamin D intake. Discuss baseline DXA scan (bone density test) with your doctor, especially if at higher risk. Slower, sustainable weight loss + lifestyle changes help mitigate losses"

@EricLDaugh A $50 monthly copay could be a major access shift for seniors. When GLP-1s become more affordable, clear patient education matters even more: benefits, side effects, muscle loss, long-term use, and what happens after stopping. amazon.com/dp/B0GFDG6B2X

🚨 NOW: President Trump announces American seniors will be able to get weight-loss drugs like OZEMPIC for only $50 PER MONTH after previously costing $1,300 96% SAVINGS! Huge win, PROMISE KEPT 🇺🇸 "I'm thrilled to announce that starting on July 1st, we will also provide Medicare patients with the coverage for weight loss drugs like Ozempic."

@cspan If this becomes reality, GLP-1s move from a high-cost private treatment to a major Medicare policy issue. A $50 copay changes access—but patients still need clear guidance on risks, side effects, long-term use, and what happens after stopping. amazon.com/dp/B0GFDG6B2X

President Trump: "Starting on July 1, we will also provide Medicare patients with the coverage for weight loss drugs like Ozempic, Zepbound, Wegovy. Will be available for $50 a month."

@PeptideList Exactly. The maintenance phase may be the most underestimated part of GLP-1 treatment. People need to understand what can happen after stopping: appetite return, rebound, dose decisions, muscle preservation, and long-term planning. More context here: amazon.com/dp/B0GFDG6B2X

The first year gets all the attention. The stop/maintenance phase is where patients are least prepared. GLP-1s are not just “take it, lose weight, stop.” Rebound, appetite return, dose strategy, and provider quality all matter. x.com/WSJ/status/205…

@adam_dorr That may be the right frame. GLP-1s are not just a weight-loss category—they could reshape healthcare, food demand, pharma, insurance, consumer habits, and long-term prevention. The bigger picture is what most people are still missing. amazon.com.au/dp/B0GFDG6B2X/

Ozempic and other GLP-1s today are like dial-up Internet in 1993. Most have no idea how enormous this tidal wave of disruption is actually going to be within just a few years.

The GLP 1 story is not just pharmacology. The missing product is continuous care: nutrition, muscle preservation, labs, mental health and follow up. A prescription without a care path becomes churn. x.com/i/status/20505…

@martinvars Exactly. The medication is only one part of the GLP-1 story. Without nutrition, resistance training, lab monitoring, mental health support, and a plan for long-term use or stopping, patients are left with too many unanswered questions. More context here: amazon.com/dp/B0GFDG6B2X

@newstart_2024 Great example of how basic science can reshape medicine. The Gila monster story also shows why GLP-1s are more than a “weight loss trend”: they act across gut, brain, appetite, metabolism, and even reward pathways. We cover that broader picture here: amazon.com/dp/B0GFDG6B2X

GLP-1 drugs are everywhere right now — but their story traces back to a venomous desert lizard. Andrew Huberman explained on Gwyneth Paltrow’s goop podcast: researchers studying Gila monsters, which can survive long periods without food, isolated exendin-4 from their venom. This peptide mimics human GLP-1 but is more resistant to enzymatic breakdown. That finding helped lead to the development of modern GLP-1 receptor agonists used for type 2 diabetes and weight management. It’s a clear example of how curiosity about animal physiology can contribute to medical advances. This matters because so much of today’s most effective treatments still originate from basic, curiosity-driven science rather than targeted corporate R&D alone. Huberman notes the practical realities: these drugs act on receptors throughout the brain and gut, which can lead to side effects such as muscle loss (often reduced with resistance training) and gastrointestinal discomfort, especially early on. Personally, stories like this remind me why I stay optimistic about science — nature has already solved problems we’re only beginning to understand. What surprising connection between animal biology and human medicine have you come across?

@NIH A 40% reduction in heavy drinking is a striking signal. The GLP-1 story is clearly moving beyond weight loss, especially around reward pathways, craving, and addiction research. We also discuss this emerging angle here: amazon.com/dp/B0GFDG6B2X

NEWS: Weekly GLP-1 reduced heavy drinking by more than 40%. 🥃 Read the full story ➡️ bit.ly/3QDXnXP

@TheLancet Important finding. If GLP-1s can reduce heavy drinking in people with obesity and alcohol use disorder, this may become one of their most significant uses beyond weight loss. We also discuss this emerging angle here: amazon.com/dp/B0GFDG6B2X

Alcohol use disorder accounts for 5% of deaths worldwide annually, and there is an urgent need for new treatments. A new study found that GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity: spkl.io/6012AfU04

@Reuters Medicare coverage could turn GLP-1s from a private-access issue into a national healthcare question. Cost, eligibility, long-term use, and what happens after stopping all matter here. More context here: amazon.com/dp/B0GFDG6B2X

Trump says U.S. to provide GLP-1 drugs for Medicare patients reut.rs/3Rfzw0B reut.rs/3Rfzw0B

@lindayaX @eMedHealth Coverage is becoming one of the biggest GLP-1 issues. For many patients, the question is no longer just “do these drugs work?” but whether access, cost, long-term use, and stopping treatment are being handled responsibly. We cover it here: amazon.com/dp/B0GFDG6B2X

24 million people lost GLP-1 coverage last year. Fix the problem. Don't cut the benefit. @eMedHealth

@BhavanChand This is where real-world GLP-1 adoption may look very different from clinical trial headlines. In price-sensitive markets, “good enough + affordable” can matter more than the most advanced mechanism. Cost and access are a huge part of the story: amazon.com/dp/B0GFDG6B2X

Generic Semaglutide is working really well People are losing solid weight, and for most, it’s honestly enough to get the job done A lot of users who were on Mounjaro are now quietly switching to generic Semaglutide Yes, Mounjaro (Tirzepatide) is a dual agonist and clinically better for weight loss than Semaglutide alone - No debate there But here’s the reality in India: Mounjaro costs ₹12,000+ per month Generic Semaglutide costs just ₹800 In a super price-sensitive market like India, will most people actually care about “dual agonism”? Especially when most people say, " I just want to lose a few kilos" to look and feel better in clothes For the average person, the answer seems to be: No Will people spend 12x more on mounjaro when they are getting the job done with generic semaglutide?